Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide - PubMed (original) (raw)
. 2010 Jul 1;145(1):17-25.
doi: 10.1016/j.jconrel.2010.03.007. Epub 2010 Mar 20.
Xianhuo Wang, Yongsheng Wang, Li Yang, Jia Hu, Wenjing Xiao, Afu Fu, Lulu Cai, Xia Li, Xia Ye, Yalin Liu, Wenshuang Wu, Ximing Shao, Yongqiu Mao, Yuquan Wei, Lijuan Chen
Affiliations
- PMID: 20307599
- DOI: 10.1016/j.jconrel.2010.03.007
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide
Xiang Chen et al. J Control Release. 2010.
Abstract
Fibroblast growth factor receptors (FGFRs), overexpressed on the surface of a variety of tumor cells and on tumor neovasculature in situ, are potential targets for tumor- and vascular-targeting therapy. This study aimed to develop a FGFR-mediated drug delivery system to target chemotherapeutic agents to FGFR-overexpressed tumor cells and tumor neovasculature endothelial cells in vitro and in vivo. Here we designed a truncated human basic fibroblast growth factor peptide (tbFGF), which was attached to the surface of cationic liposomal doxorubicin (LPs-DOX) and paclitaxel (LPs-PTX) via electrostatic force. Then we characterized the tbFGF-modified liposome (tbFGF-LPs) and examined internalization of doxorubicin in tumor cells (TRAMP-C1, B16) and HUVEC cells in vitro. In vivo, we evaluated the biodistribution and antitumor efficacy of tbFGF-LPs-DOX and tbFGF-LPs-PTX in C57BL/6J mice bearing TRAMP-C1 prostate carcinoma and B16 melanoma, respectively. The tbFGF-LPs-DOX significantly improved the uptake of doxorubicin in TRAMP-C1, B16 and HUVEC cells, respectively. Biodistribution study in B16 tumor-bearing mice showed that tbFGF-LPs-PTX achieved 7.1-fold (72.827+/-7.321mgh/L vs 10.292+/-0.775mgh/L, mean+/-SD, P<0.01) accumulation of paclitaxel in tumor tissue than those of free paclitaxel. More importantly, treatment of tumor-bearing mice with tbFGF-LPs-DOX and tbFGF-LPs-PTX showed the significant inhibition in tumor growth and improvement in survival rate as compared with mice treated with free and liposomal drugs in TRAMP-C1 and B16 tumor models, respectively. Furthermore, repeated intravenous administration of tbFGF-LPs-DOX/PTX did not induce anti-bFGF antibodies. These results suggested that this FGFR-mediated drug delivery system may provide a new treatment strategy for tumors which overexpress FGFRs.
2010 Elsevier B.V. All rights reserved.
Similar articles
- Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice.
Wang X, Deng L, Chen X, Pei H, Cai L, Zhao X, Wei Y, Chen L. Wang X, et al. J Pharm Sci. 2011 Mar;100(3):1196-205. doi: 10.1002/jps.22348. Epub 2010 Sep 21. J Pharm Sci. 2011. PMID: 20860011 - A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells.
Cai L, Qiu N, Li X, Luo K, Chen X, Yang L, He G, Wei Y, Chen L. Cai L, et al. Int J Pharm. 2011 Apr 15;408(1-2):173-82. doi: 10.1016/j.ijpharm.2011.01.042. Epub 2011 Jan 26. Int J Pharm. 2011. PMID: 21277964 - Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
Xiao W, Chen X, Yang L, Mao Y, Wei Y, Chen L. Xiao W, et al. Int J Pharm. 2010 Jun 30;393(1-2):119-26. doi: 10.1016/j.ijpharm.2010.04.018. Epub 2010 Apr 21. Int J Pharm. 2010. PMID: 20416367 - Liposomal nanomedicines in the treatment of prostate cancer.
Kroon J, Metselaar JM, Storm G, van der Pluijm G. Kroon J, et al. Cancer Treat Rev. 2014 May;40(4):578-84. doi: 10.1016/j.ctrv.2013.10.005. Epub 2013 Oct 25. Cancer Treat Rev. 2014. PMID: 24216226 Review. - Bacterial ghosts (BGs)--advanced antigen and drug delivery system.
Kudela P, Koller VJ, Lubitz W. Kudela P, et al. Vaccine. 2010 Aug 16;28(36):5760-7. doi: 10.1016/j.vaccine.2010.06.087. Epub 2010 Jul 7. Vaccine. 2010. PMID: 20619379 Review.
Cited by
- Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy.
Zhang X, Men K, Zhang Y, Zhang R, Yang L, Duan X. Zhang X, et al. Int J Nanomedicine. 2019 Apr 23;14:2733-2751. doi: 10.2147/IJN.S198747. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31118608 Free PMC article. - Fluorescence Characterization of Gold Modified Liposomes with Antisense N-myc DNA Bound to the Magnetisable Particles with Encapsulated Anticancer Drugs (Doxorubicin, Ellipticine and Etoposide).
Skalickova S, Nejdl L, Kudr J, Ruttkay-Nedecky B, Jimenez AM, Kopel P, Kremplova M, Masarik M, Stiborova M, Eckschlager T, Adam V, Kizek R. Skalickova S, et al. Sensors (Basel). 2016 Feb 25;16(3):290. doi: 10.3390/s16030290. Sensors (Basel). 2016. PMID: 26927112 Free PMC article. - Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy.
Enriquez GG, Rizvi SA, D'Souza MJ, Do DP. Enriquez GG, et al. Int J Nanomedicine. 2013;8:1393-402. doi: 10.2147/IJN.S43479. Epub 2013 Apr 10. Int J Nanomedicine. 2013. PMID: 23630421 Free PMC article. - VEGF-D-enhanced lymph node metastasis of ovarian cancer is reversed by vesicular stomatitis virus matrix protein.
Qi X, Du L, Chen X, Chen L, Yi T, Chen X, Wen Y, Wei Y, Zhao X. Qi X, et al. Int J Oncol. 2016 Jul;49(1):123-32. doi: 10.3892/ijo.2016.3527. Epub 2016 May 17. Int J Oncol. 2016. PMID: 27211072 Free PMC article. - Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index.
Kallus S, Englinger B, Senkiv J, Laemmerer A, Heffeter P, Berger W, Kowol CR, Keppler BK. Kallus S, et al. Nanomedicine. 2018 Nov;14(8):2632-2643. doi: 10.1016/j.nano.2018.08.001. Epub 2018 Aug 16. Nanomedicine. 2018. PMID: 30121385 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical